189 related articles for article (PubMed ID: 23902965)
21. Hydrogen sulfide donors alleviate itch secondary to the activation of type-2 protease activated receptors (PAR-2) in mice.
Coavoy-Sánchez SA; Rodrigues L; Teixeira SA; Soares AG; Torregrossa R; Wood ME; Whiteman M; Costa SKP; Muscará MN
Pharmacol Res; 2016 Nov; 113(Pt A):686-694. PubMed ID: 27720932
[TBL] [Abstract][Full Text] [Related]
22. Methods for preclinical assessment of antipruritic agents and itch mechanisms independent of mast-cell histamine.
Kuraishi Y
Biol Pharm Bull; 2015; 38(5):635-44. PubMed ID: 25947907
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the effects of anti-pruritic drugs on scratch responses using histamine H1 receptor-deficient mice.
Sugimoto Y; Nakamura Y; Hossen MA; Watanabe T; Kamei C
Eur J Pharmacol; 2003 May; 470(1-2):113-6. PubMed ID: 12787839
[TBL] [Abstract][Full Text] [Related]
24. Pharmacologic advances in the systemic treatment of itch.
Summey BT; Yosipovitch G
Dermatol Ther; 2005; 18(4):328-32. PubMed ID: 16297005
[TBL] [Abstract][Full Text] [Related]
25. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review.
Phan NQ; Bernhard JD; Luger TA; Ständer S
J Am Acad Dermatol; 2010 Oct; 63(4):680-8. PubMed ID: 20462660
[TBL] [Abstract][Full Text] [Related]
26. Chronic pruritus: targets, mechanisms and future therapies.
Pogatzki-Zahn E; Marziniak M; Schneider G; Luger TA; Ständer S
Drug News Perspect; 2008 Dec; 21(10):541-51. PubMed ID: 19221635
[TBL] [Abstract][Full Text] [Related]
27. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820.
Togashi Y; Umeuchi H; Okano K; Ando N; Yoshizawa Y; Honda T; Kawamura K; Endoh T; Utsumi J; Kamei J; Tanaka T; Nagase H
Eur J Pharmacol; 2002 Jan; 435(2-3):259-64. PubMed ID: 11821035
[TBL] [Abstract][Full Text] [Related]
28. Current and emerging drugs for the treatment of pruritus: an update of the literature.
Mahmoud RH; Brooks SG; Yosipovitch G
Expert Opin Pharmacother; 2024 Apr; 25(6):655-672. PubMed ID: 38682595
[TBL] [Abstract][Full Text] [Related]
29. Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases.
Lim KM; Park YH
Arch Pharm Res; 2012 Mar; 35(3):393-6. PubMed ID: 22477184
[TBL] [Abstract][Full Text] [Related]
30. Topical capsaicin. The fire of a 'hot' medicine is reignited.
Papoiu AD; Yosipovitch G
Expert Opin Pharmacother; 2010 Jun; 11(8):1359-71. PubMed ID: 20446852
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-31 and interleukin-31 receptor: New therapeutic targets for atopic dermatitis.
Nakashima C; Otsuka A; Kabashima K
Exp Dermatol; 2018 Apr; 27(4):327-331. PubMed ID: 29524262
[TBL] [Abstract][Full Text] [Related]
32. Chronic pruritus: From pathophysiology to drug design.
Martins MS; Almeida IF; Cruz MT; Sousa E
Biochem Pharmacol; 2023 Jun; 212():115568. PubMed ID: 37116666
[TBL] [Abstract][Full Text] [Related]
33. Current treatment strategies in refractory chronic pruritus.
Pereira MP; Mittal A; Ständer S
Curr Opin Pharmacol; 2019 Jun; 46():1-6. PubMed ID: 30530232
[TBL] [Abstract][Full Text] [Related]
34. Spontaneous scratching behaviour in DS-Nh mice as a possible model for pruritus in atopic dermatitis.
Yoshioka T; Hikita I; Asakawa M; Hirasawa T; Deguchi M; Matsutani T; Oku H; Horikawa T; Arimura A
Immunology; 2006 Jul; 118(3):293-301. PubMed ID: 16827890
[TBL] [Abstract][Full Text] [Related]
35. Pathogenesis and treatment of pruritus in cholestasis.
Kremer AE; Beuers U; Oude-Elferink RP; Pusl T
Drugs; 2008; 68(15):2163-82. PubMed ID: 18840005
[TBL] [Abstract][Full Text] [Related]
36. The effect of azelastin hydrochloride on pruritus and leukotriene B4 in hemodialysis patients.
Kanai H; Nagashima A; Hirakata E; Hirakata H; Okuda S; Fujimi S; Fujishima M
Life Sci; 1995; 57(3):207-13. PubMed ID: 7596227
[TBL] [Abstract][Full Text] [Related]
37. SAR and biological evaluation of 3-azabicyclo[3.1.0]hexane derivatives as μ opioid ligands.
Lunn G; Roberts LR; Content S; Critcher DJ; Douglas S; Fenwick AE; Gethin DM; Goodwin G; Greenway D; Greenwood S; Hall K; Thomas M; Thompson S; Williams D; Wood G; Wylie A
Bioorg Med Chem Lett; 2012 Mar; 22(6):2200-3. PubMed ID: 22357342
[TBL] [Abstract][Full Text] [Related]
38. Opioid-induced pruritus: an update.
Reich A; Szepietowski JC
Clin Exp Dermatol; 2010 Jan; 35(1):2-6. PubMed ID: 19663845
[TBL] [Abstract][Full Text] [Related]
39. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus.
Dunford PJ; Williams KN; Desai PJ; Karlsson L; McQueen D; Thurmond RL
J Allergy Clin Immunol; 2007 Jan; 119(1):176-83. PubMed ID: 17208599
[TBL] [Abstract][Full Text] [Related]
40. Targeting TRP ion channels for itch relief.
Zhang X
Naunyn Schmiedebergs Arch Pharmacol; 2015 Apr; 388(4):389-99. PubMed ID: 25418889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
